Gline Matthew
CEO
Gline Matthew has filed 7 SEC Form 4 filings (17 transaction rows) across 1 company, with disclosures dating back to 2025. 6 of those filings fall inside the rolling window. Most recent filing: Oct 20, 2026.
On the most recent filing, Gline Matthew is listed as CEO at Roivant Sciences Ltd. Inside the rolling window, Gline Matthew reported no open-market purchases and 2 open-market sales totaling $46.2M in ROIV. The largest disclosed transaction in the window is a sale of 1,740,000 ROIV shares on Dec 15, 2025, worth $37.7M.
Companies traded
Other insiders at ROIV
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$46.2M
reported sales (SEC code S)
Companies
1
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Sep 18, 2025 | ROIV | Purchase | $50K |
Frequently asked questions
How many SEC Form 4 filings has Gline Matthew made?
Gline Matthew has filed 7 SEC Form 4 filings (17 transaction rows) across 1 company since 2025.
Which companies does Gline Matthew trade?
Gline Matthew has filed SEC Form 4 disclosures for 1 company, including ROIV.
When was Gline Matthew's most recent SEC Form 4 filing?
Gline Matthew's most recent SEC Form 4 filing on Tracefour is dated Oct 20, 2026.
What is Gline Matthew's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Gline Matthew is listed as CEO.
What is Gline Matthew's total buy and sell value in the current window?
Inside the rolling retention window, Gline Matthew bought $0 and sold $46.2M based on SEC Form 4 filings.
What was Gline Matthew's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,740,000 ROIV shares on 2025-12-15, worth $37.7M, per SEC Form 4 filings.